Renishaw Plc · LSE:RSW
Renishaw — Investor Day (May 2014)
8 slides from Renishaw's investor day presentation, May 15, 2014
Slide 1: Investor Day
Investor Day Renishaw Diagnostics Ltd 15th May 2014 Presented by Rupert Jones
Slide 2: Customer needs
Customer needs Our customers will ultimately be medium to large hospital labs engaged in pathogen (disease causing micro-organisms) testing, from ‘at risk’ or symptomatic patient groups. Health trust managers are constantly under pressure to reduce costs and improve patient outcomes. Key to achievin
Slide 3: Customer needs
Customer needs The RenDx system provides automated, high sensitivity testing for multiple pathogens from a single patient sample. This innovative platform has the potential to change clinical practice by: • Providing more accurate diagnosis for precise treatment selection and improve patient managem
Slide 4: Engineering Solution – RenDx
Engineering Solution – RenDx • Currently available and in use on a ‘Research Use Only’ basis, the platform has been very well received by early adopters • It uses conventional techniques to achieve groundbreaking specificity and sensitivity • The RenDx platform utilises standard microbiology lab pra
Slide 5: The RenDx solution
Cm” Watch me on Youaflity”
Slide 6: Renishaw’s first ‘targeted solution’ – Fungiplex™ assay
Renishaw’s first ‘targeted solution’ – Fungiplex™ assay Allows detection of most common causative agents of invasive fungal infection (IFD) Candida Aspergillus • IFDs are predominantly diseases of Candida spp.* Aspergillus spp.* the diseased C. albicans A. fumigatus • The two most prevalent pathogen
Slide 7: The RenDx solution
The RenDx solution • Precision diagnostics rather than broad spectrum treatments • Why is this a better approach? • Non-specific signs and symptoms of infection • Conventional diagnostic techniques sub-optimal and often require pre- judgement • Delays in treatment lead to poorer patient outcomes • L
Slide 8: RENISHAW
RENISHAW apply innovation™ RenDx:: Multiplex Assay System ‘e,